This study gave us the opportunity to expand our understanding of SRF’s role in docetaxel resistance, in the context of AR negative and docetaxel resistant PC-3 cells, and clinical tissues from castrate and docetaxel resistant prostate cancer. This evidence concerns the gene SRF and prostate cancer.